TXMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for TherapeuticsMD Inc (TXMD.O) is 10.31, compared to its 5-year average forward P/E of 0.03. For a more detailed relative valuation and DCF analysis to assess TherapeuticsMD Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.03

Current PE

10.31

Overvalued PE

10.06

Undervalued PE

-10.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.21

Current EV/EBITDA

0.14

Overvalued EV/EBITDA

2.09

Undervalued EV/EBITDA

-4.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.96

Current PS

2.08

Overvalued PS

8.94

Undervalued PS

-1.01

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 399.5% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 399.5% over the last month.

Sold

Bought

TXMD News & Events

Events Timeline

No data

News

9.5

01-08NASDAQ.COM

ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept

9.5

2025-08-13NASDAQ.COM

TherapeuticsMD Swings to Profit in Q2

9.5

2025-08-12NASDAQ.COM

TherapeuticsMD Q2 Earnings Summary

People Also Watch

Frequently Asked Questions

What is TherapeuticsMD Inc (TXMD) stock price today?

The current price of TXMD is 2.06 USD — it has increased 0 % in the last trading day.

What is TherapeuticsMD Inc (TXMD)'s business?

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

What is the price predicton of TXMD Stock?

Wall Street analysts forecast TXMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is TherapeuticsMD Inc (TXMD)'s revenue for the last quarter?

TherapeuticsMD Inc revenue for the last quarter amounts to 784.00K USD, increased 43.33 % YoY.

What is TherapeuticsMD Inc (TXMD)'s earnings per share (EPS) for the last quarter?

TherapeuticsMD Inc. EPS for the last quarter amounts to 0.01 USD, decreased -120.00 % YoY.

What changes have occurred in the market's expectations for TherapeuticsMD Inc (TXMD)'s fundamentals?

The market is revising No Change the revenue expectations for TXMD for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 94.34%.

How many employees does TherapeuticsMD Inc (TXMD). have?

TherapeuticsMD Inc (TXMD) has 1 emplpoyees as of January 09 2026.

What is TherapeuticsMD Inc (TXMD) market cap?

Today TXMD has the market capitalization of 23.84M USD.